Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...

Alumis (NASDAQ:ALMS) stock surges 14% after the company reached a licensing deal with Kaken (KKPCF) for its skin disorder ...

Charles Schwab Investment Management Inc. increased its holdings in shares of Alumis Inc. (NASDAQ:ALMS – Free Report) by 4.4% ...

Stock analysts at HC Wainwright upped their Q1 2025 EPS estimates for Alumis in a report released on Wednesday, March 26th.

Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties o ...

Last week’s deal-making news included US biotech Alumis signing a licensing agreement with Japan’s Kaken Pharma for its ...

Alumis (ALMS) and Kaken Pharmaceutical announced that the companies have entered into a collaboration and licensing agreement to develop, ...

Alumis shares rose after the company signed a licensing agreement, worth $40 million in the short-term, with Tokyo-based Kaken Pharmaceutical. The stock climbed 17.9% to $4.45 on Tuesday, recovering ...

California-based clinical stage biotech Alumis (Nasdaq: ALMS) today announced a collaboration and licensing agreement with Japan’s Kaken Pharmaceutical (TYO: 4521) to develop, manufacture and ...